Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Winter Storm Devin Triggers Massive Flight Cancellations and Travel Disruptions Across the U.S. 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands 
Nvidia and Groq Strike Strategic AI Inference Licensing Deal 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Lloyds Banking Group to Close Invoice Factoring Business by End of 2025 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards 
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock 
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns 
PHILADELPHIA, March 02, 2016 -- Spark Therapeutics, Inc. (“Spark”) (NASDAQ:ONCE) announced today that Jeffrey D. Marrazzo, co-founder and chief executive officer, is presenting at the Cowen 36th Annual Health Care Conference on Monday, March 7, 2016 at 4:40 pm (EST), at the Marriott Copley Place, Boston, Massachusetts.
To access the slide deck presented, please visit the "Investor Presentations" section of the Spark Therapeutics website at www.sparktx.com.
About Spark Therapeutics
Spark is a gene therapy leader seeking to transform the lives of patients with debilitating genetic diseases by developing one-time, life-altering treatments. Spark’s initial focus is on treating rare diseases where no, or only palliative, therapies exist. Spark’s most advanced product candidate, SPK-RPE65 (voretigene neparvovec), which has received both breakthrough therapy and orphan product designation, recently reported positive top-line results from a pivotal Phase 3 clinical trial for the treatment of rare blinding conditions. Spark’s validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal dystrophies, hematologic disorders and neurodegenerative diseases. Spark builds on two decades of research, development and manufacturing at The Children’s Hospital of Philadelphia, including human trials conducted across diverse therapeutic areas and routes of administration. To learn more, please visit www.sparktx.com.
Contacts Investor Relations Spark Therapeutics, Inc. Stephen W. Webster Chief Financial Officer (855) SPARKTX (1-855-772-7589) Media Ten Bridge Communications Dan Quinn (781) 475-7974 [email protected]
